title: [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 3. Opportunistic infections].
authors.affiliation: Nephrology Center, Department of Rheumatology, Toranomon Hospital, Japan.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Sumida
authors.affiliation: Nephrology Center, Department of Rheumatology, Toranomon Hospital, Japan.
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Ubara
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use; D003095:Collagen Diseases / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D003453:Cryptococcosis; D003586:Cytomegalovirus Infections; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D012307:Risk Factors; D014376:Tuberculosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D001685:Biological Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone